A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

July 22, 2015

Primary Completion Date

August 18, 2020

Study Completion Date

July 11, 2022

Conditions
Tumors
Interventions
DRUG

Lenvatinib

Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.

DRUG

Pembrolizumab

Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.

Trial Locations (64)

4604

Sørlandet Hospital, Kristiansand

Unknown

Alaska Clinical Research Center, Anchorage

Arizona Oncology Associates, Oro Valley

Arizona Oncology Associates, PC - HOPE, Site #1, Tucson

Arizona Oncology Associates, PC - HOPE, Site #2, Tucson

Arizona Oncology Associates, PC - HOPE, Site #3, Tucson

Rocky Mountain Cancer Centers, Aurora

Rocky Mountain Cancer Centers, Boulder

Rocky Mountain Cancer Centers, Colorado Springs

Rocky Mountain Cancer Centers, Site #1, Denver

Rocky Mountain Cancer Centers, Site #2, Denver

Rocky Mountain Cancer Centers, Lakewood

Rocky Mountain Cancer Centers, Littleton

Rocky Mountain Cancer Centers, Lone Tree

Rocky Mountain Cancer Centers, Longmont

Rocky Mountain Cancer Centers, Parker

Rocky Mountain Cancer Centers, Pueblo

Rocky Mountain Cancer Centers, Thornton

Baptist Health Medical Group Oncology, LLC, Site #1, Miami

Baptist Health Medical Group Oncology, LLC, Site #2, Miami

Baptist Health Medical Group Oncology, LLC, Site #3, Miami

Boca Raton Clinical Research Medical Center, Plantation

Piedmont Cancer Institue, Atlanta

The University of Chicago, Chicago

Beth Israel Deaconess Medical Center, Boston

Mass General Hospital, Boston

University of Minnesota, Masonic Cancer Center, Minneapolis

Comprehensive Cancer Centers of Nevada, Site #1, Henderson

Comprehensive Cancer Centers of Nevada, Site #2, Henderson

Comprehensive Cancer Centers of Nevada, Site #3, Henderson

Comprehensive Cancer Centers of Nevada, Site #1, Las Vegas

Comprehensive Cancer Centers of Nevada, Site #2, Las Vegas

Comprehensive Cancer Centers of Nevada, Site #3, Las Vegas

Comprehensive Cancer Centers of Nevada, Site #4, Las Vegas

New York Hematology Oncology (US Onc), Albany

Memorial Sloan Kettering at Westchester, Harrison

Memorial Sloan Kettering Cancer Center, New York

Oregon Health & Science University, Portland

University of Pennsylvania, Philadelphia

Texas Oncology-Bedford, Bedford

Texas Oncology (US Onc), Dallas

Texas Oncology, Dallas

Texas Oncology-Denton South, Denton

Texas Oncology-Fort Worth, Site #1, Fort Worth

Texas Oncology-Grapevine, Grapevine

Texas Oncology-Longview Cancer Center, Longview

Texas Oncology-Plano West, Plano

South Texas Accelerated Research Therapeutics, LLC, San Antonio

Texas Oncology-Tyler, Tyler

Texas Oncology-Waco, Site #1, Waco

Texas Oncology-Waco, Site #2, Waco

Haukeland Univerity Hospital, Bergen

Akershus Universitetssykehus HF, Lørenskog

Oslo Univerity Hospital, Oslo

Sykehuset Østfold, Sarpsborg

Hospital Universitari Germans Trias i Pujol, Badalona

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario De Fuenlabrada, Fuenlabrada

Hospital La Paz, Madrid

Hospital Universitario Clinico San Carlos, Madrid

MD Anderson Cancer Center Madrid - España, Madrid

Parc Taulí Sabadell, Sabadell

Hospital Virgen de la Salud, Toledo

Hospital Universitari i Politécnic La Fe., Valencia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT02501096 - A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors | Biotech Hunter | Biotech Hunter